Enzastaurin
Enzastaurin is a small molecule pharmaceutical. It is currently being investigated in clinical studies. The pharmaceutical is active against protein kinase C beta type. In addition, it is known to target protein kinase C alpha type, protein kinase C delta type, and protein kinase C gamma type.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
No data
Clinical
Clinical Trials
51 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Lymphoma | D008223 | — | C85.9 | 2 | 7 | 2 | — | — | 11 |
| Glioblastoma | D005909 | EFO_0000515 | — | 1 | 3 | 2 | — | — | 5 |
| Large b-cell lymphoma diffuse | D016403 | — | C83.3 | — | 2 | 1 | — | — | 3 |
| Non-hodgkin lymphoma | D008228 | — | C85.9 | — | 2 | 1 | — | — | 3 |
| B-cell lymphoma | D016393 | — | — | — | 1 | 1 | — | — | 2 |
| Ehlers-danlos syndrome | D004535 | Orphanet_98249 | Q79.6 | — | — | 1 | — | — | 1 |
| Syndrome | D013577 | — | — | — | — | 1 | — | — | 1 |
| Type iv ehlers-danlos syndrome | D000094623 | — | — | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | — | C80 | 5 | 4 | — | — | — | 8 |
| Lung neoplasms | D008175 | HP_0100526 | C34.90 | 1 | 8 | — | — | — | 8 |
| Non-small-cell lung carcinoma | D002289 | — | — | 1 | 7 | — | — | — | 7 |
| Glioma | D005910 | EFO_0000520 | — | 3 | 2 | — | — | — | 5 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | — | 4 | — | — | — | 4 |
| Prostatic neoplasms | D011471 | — | C61 | — | 3 | — | — | — | 3 |
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | — | 3 | — | — | — | 3 |
| Colorectal neoplasms | D015179 | — | — | — | 2 | — | — | — | 2 |
| Recurrence | D012008 | — | — | 1 | 1 | — | — | — | 2 |
| Carcinoma | D002277 | — | C80.0 | — | 2 | — | — | — | 2 |
Show 17 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Central nervous system neoplasms | D016543 | — | — | 2 | — | — | — | — | 2 |
| Nervous system neoplasms | D009423 | — | — | 2 | — | — | — | — | 2 |
| Neoplasm metastasis | D009362 | EFO_0009708 | — | 1 | — | — | — | — | 1 |
| Neuroblastoma | D009447 | EFO_0000621 | — | 1 | — | — | — | — | 1 |
| Leukemia | D007938 | — | C95 | 1 | — | — | — | — | 1 |
| Lymphoid leukemia | D007945 | — | C91 | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Enzastaurin |
| INN | enzastaurin |
| Description | 3-(1-methyl-3-indolyl)-4-[1-[1-(2-pyridinylmethyl)-4-piperidinyl]-3-indolyl]pyrrole-2,5-dione is a member of indoles and a member of maleimides. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | Cn1cc(C2=C(c3cn(C4CCN(Cc5ccccn5)CC4)c4ccccc34)C(=O)NC2=O)c2ccccc21 |
Identifiers
| PDB | — |
| CAS-ID | 170364-57-5 |
| RxCUI | — |
| ChEMBL ID | CHEMBL300138 |
| ChEBI ID | — |
| PubChem CID | 176167 |
| DrugBank | — |
| UNII ID | UC96G28EQF (ChemIDplus, GSRS) |
Target
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,413 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
260 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use